MSD has entered its final stage of developing combination drug 'Atozet'
MSD which was in the shadow of Pfizer and Astrazenaca in the domestic hyperlipidemia market, is seeking a reversal with composite hyperlipidemia treatment. MSD has entered its final stage of developing combination drug 'Atozet' which is composed of 'Atorvastatin' and cholesterol absorption inhibi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
